Jan Skvarka - Sep 11, 2023 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Director
Signature
/s/ Melissa B. Epperly, Attorney-in-Fact for Jan Skvarka
Stock symbol
ZNTL
Transactions as of
Sep 11, 2023
Transactions value $
-$125,238
Form type
4
Date filed
9/13/2023, 04:11 PM
Previous filing
Jun 16, 2023
Next filing
Jun 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale -$125K -5K -9.44% $25.05 48K Sep 11, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires September 14, 2023.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.76 to $25.28. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.